Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

AlzeCure Pharma

7.72 SEK+0.52 %28/8 9:58
Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+0.52 %
+20.62 %
+534.15 %
+367.62 %
+340.73 %
+149.00 %
+96.74 %
+14.16 %
-6.90 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Read more
Market cap
1.14B SEK
Turnover
1.41M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
11/11
2026

Interim report Q3'26

23/2
2027

Annual report '26

Press release2026-08-27 10:00

AlzeCure Pharma presenterar på Pareto Securities 17th Annual Healthcare Conference den 2 september

AlzeCure Pharma
Press release2026-08-27 10:00

AlzeCure Pharma to present at the Pareto Securities 17th Annual Healthcare Conference on September 2

AlzeCure Pharma
Regulatory press release2026-08-26 08:00

AlzeCure offentliggör delårsrapport för januari – juni 2026

AlzeCure Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-26 08:00

AlzeCure publishes its interim report for January – June 2026

AlzeCure Pharma
Press release2026-08-18 10:00

AlzeCure erhåller upfront-betalning om 10 miljoner USD och slutför den initiala transaktionen med Lilly

AlzeCure Pharma
Press release2026-08-18 10:00

AlzeCure receives a USD 10 million upfront payment and completes initial transaction with Lilly

AlzeCure Pharma
Press release2026-08-12 10:00

AlzeCure får totalt 12 miljoner USD i upfront-betalning och slutför den initiala transaktionen med QuantumCell

AlzeCure Pharma
Press release2026-08-12 10:00

AlzeCure receives a total upfront payment of USD 12 million and completes the initial transaction with QuantumCell

AlzeCure Pharma
Third party research2026-08-05 09:18

AlzeCure: Minskad finansiell risk - Analysguiden

Alzecure har på kort tid sålt rättigheterna till bolagets båda Alzheimer-projekt NeuroRestore och Alzstatin. Under perioden Q2-Q3 drygas kassan ut med 240 miljoner SEK. Alzstatin tas över av Eli Lilly och vi räknar med att fokus på detta projekt ökar...

AlzeCure Pharma
Press release2026-08-05 09:10

Analysguiden: ANALYS AlzeCure Pharma: Minskad finansiell risk

AlzeCure Pharma
Regulatory press release2026-08-03 08:00

AlzeCure Pharma beslutar om riktad nyemission till QuantumCell

AlzeCure Pharma
Regulatory press release2026-08-03 08:00

AlzeCure Pharma resolves on a directed share issue to QuantumCell

AlzeCure Pharma
Regulatory press release2026-07-02 08:00

Utfall i AlzeCures företrädesemission

AlzeCure Pharma
Regulatory press release2026-07-02 08:00

Final outcome of AlzeCure’s rights issue

AlzeCure Pharma
Regulatory press release2026-07-01 07:00

AlzeCure Pharma enters an out-licensing and collaboration agreement with QuantumCell ApS for the NeuroRestore ACD856 project

AlzeCure Pharma
Regulatory press release2026-07-01 07:00

AlzeCure Pharma ingår utlicensierings- och samarbetsavtal med QuantumCell ApS för NeuroRestore-projektet ACD856

AlzeCure Pharma
Regulatory press release2026-06-29 17:30

Kommuniké från årsstämma i AlzeCure Pharma den 29 juni 2026

AlzeCure Pharma
Regulatory press release2026-06-29 17:30

Communiqué from the annual general meeting of AlzeCure Pharma on 29 June 2026

AlzeCure Pharma
Press release2026-06-16 10:00

Positiva resultat i den kliniska fas Ib-studien med NeuroRestore ACD856 som utvecklas mot Alzheimers

AlzeCure Pharma
Press release2026-06-16 10:00

Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's

AlzeCure Pharma